Literature DB >> 9569317

MR-based assessment of vascular morphology and function.

J F Debatin1, T F Hany.   

Abstract

Initially, time-of-flight angiography found its way into clinical routine for imaging vascular morphology. In conjunction with phase-contrast imaging, functional and morphological assessment of vascular pathology became possible. The flow dependence and associated artifacts inherent to these techniques have restricted the clinical use of these magnetic resonance angiography (MRA) techniques to the extra- and intracranial arterial, as well as the systemic and portal, venous systems. With the advent of high-performance gradient systems a new, promising MRA strategy has been developed: contrast-enhanced 3D MR angiography. It is based on the combination of rapid 3D imaging and the T1-shortening effect of intravenously infused paramagnetic contrast. This review provides a technical overview and critically discusses the clinical application for the different MRA techniques regarding morphological as well as functional assessment of the vascular system.

Mesh:

Substances:

Year:  1998        PMID: 9569317     DOI: 10.1007/s003300050429

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

Review 1.  Congenital diseases of the thoracic aorta. Role of MRI and MRA.

Authors:  Vincenzo Russo; Matteo Renzulli; Cesare La Palombara; Rossella Fattori
Journal:  Eur Radiol       Date:  2005-10-26       Impact factor: 5.315

2.  3D time-of-flight MR angiography of the intracranial vessels: optimization of the technique with water excitation, parallel acquisition, eight-channel phased-array head coil and low-dose contrast administration.

Authors:  O Ozsarlak; J W Van Goethem; P M Parizel
Journal:  Eur Radiol       Date:  2004-07-31       Impact factor: 5.315

Review 3.  Acquired diseases of the thoracic aorta: role of MRI and MRA.

Authors:  Vincenzo Russo; Matteo Renzulli; Katia Buttazzi; Rossella Fattori
Journal:  Eur Radiol       Date:  2005-10-13       Impact factor: 7.034

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.